BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Collaboration

  Boehringer Ingelheim Bets up to Nearly $1B in ADC Play With AimedBio Deal

  2025 has been a busy year for Boehringer Ingelheim, which has so far inked at least five hefty partnerships—including its latest one with South Korea’s AimedBio for an antibody-drug conjugate therapy for cancer.

  October 15, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  IN PARTNERSHIP WITH TRILINK BIOTECHNOLOGIES

  Webinar: Design, Build, and Encapsulate: Transforming Digital Sequences into High-Quality, Ready-to-Test mRNA

  This webinar, tailored for scientists in academia, biotech, and pharma, explores how intelligent mRNA designs can reduce experimental workloads and improve mRNA performance and efficacy.
  

  October 15, 2025

   · 

  1 min read

   · 

  BioSpace Insights
• 

  C-suite

  Biotech Leader Gujrathi Holds Up a Mirror for Other Women

  Sheila Gujrathi, former CEO of Gossamer Bio, has written a new book that aims to offer the type of leadership manual she never had in her early career.

  October 15, 2025

   · 

  5 min read

   · 

  Annalee Armstrong
• 

  Funding

  Pelage Pharmaceuticals Raises $120 Million To Grow Hair Loss Program

  The company is pursuing a Phase III trial for its topical stem cell-rejuvenating molecule that aims to reactivate hair growth.

  October 15, 2025

   · 

  2 min read

   · 

  Dan Samorodnitsky
• 

  GLP-1

  Lilly’s Oral GLP-1 Bests Another Big Pharma Bestseller in Phase III Diabetes Trial

  After beating Novo Nordisk’s semaglutide last month, Lilly’s much anticipated oral candidate orforglipron has taken down AstraZeneca’s Farxiga in a head-to-head trial.

  October 15, 2025

   · 

  2 min read

   · 

  Annalee Armstrong
• 

  Gene therapy

  Sarepta’s Not Done With Gene Therapy Yet as LGMD Asset Yields Promising Data

  Despite announcing a broad pivot to siRNA earlier this year, Sarepta is following through with an investigational gene therapy: its limb-girdle muscular dystrophy candidate. But the treatment’s path forward, analysts say, is highly uncertain.

  October 15, 2025

   · 

  6 min read

   · 

  Tristan Manalac
• 

  Rare diseases

  Novo Offers up to $2.1B for Omeros’ Complement Drug To Expand Rare Disease Work

  Novo Nordisk strikes another deal, this time with Omeros, amid a broader pipeline restructuring that recently claimed its cell therapy work.

  October 15, 2025

   · 

  2 min read

   · 

  Dan Samorodnitsky
• 

  Immuno-oncology

  Cartography Pushes Sequencing to the Limit To Find Bananas in 100 Apples

  The startup, launched out of CEO Kevin Parker’s grad school idyll during the COVID lockdowns, is primed to find new targets where Big Pharmas won’t dare.

  October 15, 2025

   · 

  4 min read

   · 

  Dan Samorodnitsky
• 

  Career Advice

  Job Hugging Won’t Save You: The Hidden Risk of Playing It Safe

  In a volatile industry, staying put might seem like a smart bet, but job hugging can quietly erode your visibility, growth and future opportunities.

  October 15, 2025

   · 

  3 min read

   · 

  Angela Justice
• 

  Job search strategy

  More Marathon Than Sprint: Getting Biopharma Jobs Often Takes 4+ Months, BioSpace Finds

  Biopharma professionals aren’t typically hired right away, based on a BioSpace LinkedIn poll. In the past year, only about one-third of respondents found employment in three months or less. Several who did share their keys to success.

  October 15, 2025

   · 

  5 min read

   · 

  Angela Gabriel